Molecular Basis of Restenosis and Novel Issues of Drug-Eluting Stents
Authors:
Open Access
- 1 January 2009
- journal article
- review article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 73 (4) , 615-621
Abstract
Restenosis after stent deployment is an overreaction of the wound healing response after vascular injury, and is characterized by the sequence of inflammation, granulation, extracellular matrix remodeling, and smooth muscle cell (SMC) proliferation and migration. In contrast, reendothelialization of at least part of the injured vessel surface, which is essential in the wound healing process, may occur at the site of stenting. Recent advances in drug-eluting stents (DES) have substantially reduced restenosis, but do not contribute to improve long-term prognosis, compared with bare metal stents (BMS). One of the reasons may be that reendothelialization is impaired after DES stenting. Regenerated endothelial cells and proliferated SMCs in the neointima are both in part derived from their progenitor cells, which are mobilized from bone marrow to injured vessel sites and differentiate into both vascular endothelial cells and SMCs. DES inhibits mobilization and differentiation of endothelial and smooth muscle progenitor cells, and thus not only inhibits restenosis but also impairs reendothelialization, which may lead to late stent thrombosis. To improve long-term prognosis in the DES era, adjunctive medical treatments inducing early reendothelialization, but inhibiting SMC proliferation, would be required. (Circ J 2009; 73: 615 - 621)Keywords
This publication has 73 references indexed in Scilit:
- Optimal Medical Therapy with or without PCI for Stable Coronary DiseaseNew England Journal of Medicine, 2007
- Mobilization of CD34-Positive Bone Marrow–Derived Cells After Coronary Stent ImplantationCirculation, 2007
- Effects of Tacrolimus or Sirolimus on Proliferation of Vascular Smooth Muscle and Endothelial CellsJournal of Cardiovascular Pharmacology, 2006
- Severe Endothelial Dysfunction After Sirolimus-Eluting Stent ImplantationCirculation, 2006
- The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiationAmerican Journal of Physiology-Cell Physiology, 2004
- Drug-eluting stents: new era and new concernsPostgraduate Medical Journal, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Stent-Induced Expression and Activation of the Leukocyte Integrin Mac-1 Is Associated With Neointimal Thickening and RestenosisCirculation, 2003
- Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery.Journal of Clinical Investigation, 1997
- Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplastyJACC, 1996